E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Glucose tolerance |
glucose tolerantie |
|
E.1.1.1 | Medical condition in easily understood language |
Glucose tolerance: the switch between fatoxidation in the fasted state and glucose oxidation in the fed state. |
Glucose tolerantie : het kunnen wisselen tussen vetverbranding in de gevaste staat en suikerverbranding in de gevoede staat. E |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives are to investigate whether L-carnitine supplementatiion improves insulin insulin sensitivity and metabolic flexibility in type 2 diabetic patients with a low carnitine status. |
Om te onderzoeken of carnitine supplementatie insuline gevoeligheid en metabole flexibiliteit verbeterd in type 2 diabetes patienten met een lage carnitine status. |
|
E.2.2 | Secondary objectives of the trial |
To examine the effects of carnitine supplementation on intrahepatic lipid, body composition, sleep quality, quality of life, physical performance, cognition, acetylcarnitine formation, CrAT activity, acylcarnitine profiles and lipid profiles in type 2 diabetic patients with a low carnitine status |
Om het effect te onderzoeken van carnitine supplementatie in type 2 diabetes patient met een lage carnitine status op levervet, lichaamssamenstelling, kwaliteit van slaap, kwaliteit van leven, conditie, geheugen, acetylcarnitine vorming, CrAT activiteit, acylcarnitine profielen en vetprofielen. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Men and woman • Age: 40-70 years • Woman should be postmenopausal • BMI: 25-35 kg/m2 • Stable dietary habits • No use of medication interfering with investigated study parameters (as determined by responsible physician) • Use of oral glucose lowering medication (metformin only or in combination with sulfonylurea agents)
|
Mannen en vrouwen • Leeftijd: 40-70 jaar • Vrouwen moeten post-menopausaal zijn • BMI: 25-35 kg/m2 • Stabiel eetpatroon • Geen medicatiegebruik dat interfereert met de uitkomstmaten - gebruik van orale glucose medicatie |
|
E.4 | Principal exclusion criteria |
• Haemoglobin levels < 7.8 mmol/L • Uncontrolled hypertension • Use of anticoagulants • Insulin dependent type 2 diabetic patients. • No signs of active liver or kidney malfunction. • Engagement in exercise > 3 hours a week • Being vegetarian or vegan (because of altered whole body carnitine status) • Alcohol and/or drug abuse • Unstable body weight (weight gain or loss > 5kg in the last 3 months) • Significant food allergies/intolerances (seriously hampering study meals) • Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results • Medication use known to hamper subject's safety during the study procedures • Subjects with contra-indications for MRI • Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study • Subjects who do not want to be informed about unexpected medical findings • No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy |
• Haemoglobine levels < 7.8 mmol/L • Ongecontroleerde hypertensie • Gebruik van bloedverdunners Insuline afhankelijke patienten met type 2 diabetes Nier of leverfalen • Sporten > 3 uur per week • Vegetarisch of veganistisch • Alcohol en/of drugsmisbruik • Onstabiel lichaamsgewicht (gewichtstoename of -afname > 5kg in de afgelopen 3 maanden) • Voedingsallergie of intolerantie • Deelname in een andere biomedische studie binnen 1 maand voor aanvang aan de huidige studie. • Medicatie gebruik dat interfereert met de onderzochte parameters in de studie • Contra-indicaties voor de MRI • Proefpersonen die bloed willen doneren tijdens de studie of binnen 3 maanden voor aanvang van de studie • Proefpersonen die niet geïnformeerd willen worden over toevalsbevindingen • Geen actieve diebetes gerelateerd co-morbiditeiten zoals cardiovasculaire ziekten, diebetische voet, neuropathie en retinopatie |
|
E.5 End points |
E.5.1 | Primary end point(s) |
2-step hyperinsulinemic euglycemic clamp combined with tracer kinetics and indirect calorimetry: - Whole body insulin sensitivity measured as GIR in µmol/kg/min during the stable period of the insulin phase of the clamp. - Hepatic insulin sensitivity measured as EGP in µmol/kg/min. - Peripheral insulin sensitivity measured as Rd in µmol/kg/min. - Metabolic flexibility (delta RER between basal and insulin stimulated state). |
Insuline gevoeligheid van het hele lichaam weergegeven als GIR in µmol/kg/min tijdens de stabiele fase van de insuline tijdens de clamp. hepatische insuline gevoeligheid als EGP in µmol/kg/min Perifere insuline gevoeligheid als Rd in µmol/kg/min Metabole flexibiliteit ( delta RER tussen basaal en insuline) E |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After finilizing the study, meaning 36 included subjects |
Na afronding van de studie. Dus nadat 36 personen |
|
E.5.2 | Secondary end point(s) |
- Maximal acetylcarnitine concentrations after exercise (measured using the 1H-MRS cycling measurement) - Intrahepatic lipid content (measured using 1H-MRS) - Body composition (Bodpod) - Metabolites in the blood before (i.e. glucose, free fatty acids, triglycerides, cholesterol, insulin) - CrAT activity (measured in muscle biopsies) - Acylcarnitine profiles (measured in muscle biopsies) - Lipid and lipid intermediates (measured in muscle biopsies) - Functional markers of physical performance - Quality of life - Quality of sleep
|
- Maximal acetylcarnitine concentrie na inspanning - Levervet - Lichaamssamenstelling - Metabolieten in het bloed (glucose, vrije vetzuren, triglyceriden, cholesterol, insuline) - CrAT activiteit - Acylcarnitine profielen - Lipiden - Fysieke vermogen - Kwaliteit van slaap - Kwaliteit van leve |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After finilizing the study, meaning 36 included subjects |
Na afronding van de studie. Dus nadat 36 personen |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |